Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer

Table 2

Patients’ characteristics according to the number of cycles of docetaxel.

	Patients who administered ≤6 cycles of DOC (N = 21)	Patients who administered ≥7 cycles of DOC (N = 25)	value
Age (years, median, IQR)	72 (65–74)	71 (68–76)	0.808
Body mass index (kg/m^2, median, IQR)	22.8 (19.8–24.4)	23.5 (21.2–25.2)	0.275
Initial PSA (ng/mL, median, IQR)	61.2 (8.5–358.0)	159.0 (27.0–825.6)	0.209
Gleason grade (number, %)			0.585
≤2	0 (0)	0 (0)
≥3	19 (90.5)	24 (96)
Unknown	2 (9.5)	1 (4)
Definitive treatment for prostate (number, %)	5 (23.8)	6 (24.0)	>0.999
Time to CRPC after initial diagnosis (months, median, IQR)	11.0 (5.5–22.0)	15.0 (13.0–21.5)	0.064
The number of the administration of ARTs (number, median, %)	1 (1–2)	1 (1–2)	0.461
Time from diagnosis of CRPC to DOC administration (months, median, IQR)	10.2 (5.6–18.1)	11.8 (5.5–20.6)	0.651
The number of cycles of DOC (number, median, IQR)	4 (3–5)	16 (9.5–28.5)	<0.001
DOC initial dosage (mg/m^2, median, IQR)	56 (49–67.5)	54 (45–64.5)	0.380
The number of cycles of CBZ (number, median, IQR)	4 (1.5-6)	6 (3–9.5)	0.074
CBZ initial dosage (mg/m^2, median, IQR)	20 (18.8–20)	20 (20–20)	0.926
Metastasis (number, %)
Bone	21 (100)	21 (84.0)	0.114
Visceral	6 (28.6)	4 (16.0)	0.475
PSA at CBZ start (ng/mL, median, IQR)	77.0 (39.1–193.4)	67.8 (41.4–142.1)	0.508
Lactate dehydrogenase (U/L, median, IQR)	264 (222–351)	256 (223–303)	0.321
Alkaline phosphatase (U/L, median, IQR)	331 (277–527)	255 (197–495)	0.038
Hemoglobin (g/dL, median, IQR)	12.2 (103–12.9)	12.1 (11.0–12.8)	0.938

IQR = interquartile range; PSA = prostate-specific antigen; CRPC = castration-resistant prostate cancer; ART = androgen receptor-axis-targeted agent; DOC = docetaxel.